[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE69207479D1 - Verwendung der Ester von Acyl-L-Carnitin mit Gamma-Hydroxy-Buttersäure zur Herstellung von pharmazeutischen Zusammensetzungen zur Behandlung von Lebererkrankungen - Google Patents

Verwendung der Ester von Acyl-L-Carnitin mit Gamma-Hydroxy-Buttersäure zur Herstellung von pharmazeutischen Zusammensetzungen zur Behandlung von Lebererkrankungen

Info

Publication number
DE69207479D1
DE69207479D1 DE69207479T DE69207479T DE69207479D1 DE 69207479 D1 DE69207479 D1 DE 69207479D1 DE 69207479 T DE69207479 T DE 69207479T DE 69207479 T DE69207479 T DE 69207479T DE 69207479 D1 DE69207479 D1 DE 69207479D1
Authority
DE
Germany
Prior art keywords
carnitine
gamma
esters
acyl
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69207479T
Other languages
English (en)
Other versions
DE69207479T2 (de
Inventor
Fabio Zezza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of DE69207479D1 publication Critical patent/DE69207479D1/de
Application granted granted Critical
Publication of DE69207479T2 publication Critical patent/DE69207479T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69207479T 1991-05-15 1992-05-12 Verwendung der Ester von Acyl-L-Carnitin mit Gamma-Hydroxy-Buttersäure zur Herstellung von pharmazeutischen Zusammensetzungen zur Behandlung von Lebererkrankungen Expired - Fee Related DE69207479T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM910327A IT1248321B (it) 1991-05-15 1991-05-15 Uso di esteri di acil l-carnitine con l'acido gamma-idrossibutirrico per produrre composizioni farmaceutiche per il trattamento di epatopatie

Publications (2)

Publication Number Publication Date
DE69207479D1 true DE69207479D1 (de) 1996-02-22
DE69207479T2 DE69207479T2 (de) 1996-05-23

Family

ID=11400141

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69207479T Expired - Fee Related DE69207479T2 (de) 1991-05-15 1992-05-12 Verwendung der Ester von Acyl-L-Carnitin mit Gamma-Hydroxy-Buttersäure zur Herstellung von pharmazeutischen Zusammensetzungen zur Behandlung von Lebererkrankungen

Country Status (8)

Country Link
US (1) US5246967A (de)
EP (1) EP0514357B1 (de)
JP (1) JP3406614B2 (de)
AT (1) ATE132746T1 (de)
DE (1) DE69207479T2 (de)
DK (1) DK0514357T3 (de)
HK (1) HK1005848A1 (de)
IT (1) IT1248321B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
IT1263013B (it) * 1992-10-20 1996-07-23 Avantgarde Spa Esteri della l-carnitina e di alcanoil l-carnitine con l'acido glicolico o suoi esteri e composizioni farmaceutiche contenenti tali per il trattamento di affezioni cutanee.
IT1261432B (it) * 1993-03-26 1996-05-23 Sigma Tau Ind Farmaceuti Uso di acil l- carnitina gammaidrossibutirrato per il trattamento dell'alcolismo.
IT1261984B (it) * 1993-06-22 1996-06-11 Avantgarde Spa Uso di esteri della l-carnitina o di acil l- carnitine con idrossiacidi per produrre composizioni farmaceutiche per il trattamento di affezioni cutanee.
IT1261485B (it) * 1993-06-24 1996-05-23 Sigma Tau Ind Farmaceuti Uso di acil l-carnitine gamma-idrossibutirrato per il trattamento di tossicodipendenze.
IT1261828B (it) * 1993-07-14 1996-06-03 Sigma Tau Ind Farmaceuti Esteri di acil l-carnitine e composizioni farmaceutiche che li contengono per il trattamento dello shock endotossico.
IT1277898B1 (it) * 1995-08-03 1997-11-12 Mendes Srl Uso di amminoacidi basici, di acil derivati di amminoacidi basici e di loro sali farmaceuticamente accettabili per la profilassi di malattie
IT1306129B1 (it) * 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
EP3609485A4 (de) * 2017-04-11 2021-01-06 John K. Thottathil Neuartige alpha-hydroxycarbonsäure und derivate und andere grasbasierte prodrugs von gamma-hydroxybutyrat (ghb) und verwendungen davon
GB201710229D0 (en) * 2017-06-27 2017-08-09 Tdeltas Ltd Compounds for new use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2903579A1 (de) * 1978-02-03 1979-08-09 Sigma Tau Ind Farmaceuti Verwendung von acetylcarnitin und anderen acylderivaten des carnitins zur behandlung der hyperlipoproteinaemie und hyperlimpidaemie sowie arzneimittel
IT1147079B (it) * 1980-05-30 1986-11-19 Sigma Tau Ind Farmacuetiche Ri Esteri di alcossi-acil derivati della carnitina procedimento per la loro preparatione e composizioni farmaceutiche che li contengono
ATE9436T1 (de) * 1980-06-09 1984-10-15 Leopold & Co. Chem. Pharm. Fabrik Gesellschaft M.B.H. Infusionsloesung zum schutz der leber und zur verbesserung von deren funktion und verfahren zu deren herstellung.
IT1208753B (it) * 1986-07-02 1989-07-10 Sigma Tau Ind Farmaceuti L-amminoacil derivati della l-carnitina, procedimento per la loro preparazione e composizioni farmaceutiche ad attivita' epatoprotettrice che li contengono
IT1240760B (it) * 1990-02-12 1993-12-17 Sigma Tau Ind Farmaceuti Esteri di acil-l-carnitine con l'acido gamma-idrossibutirrico e composizioni farmaceutiche che li contengono per l'inibizione della degenerazione neuronale e nel trattamento del coma.
IT1240775B (it) * 1990-02-23 1993-12-17 Sigma Tau Ind Farmaceuti Esteri della l-carnitina e di acil-l-carnitine con l'acido beta-idrossibutirrico e composizioni farmaceutiche che li contengono per la inibizione della degenerazione neuronale, della proteolisi epatica e nel trattamento del coma.

Also Published As

Publication number Publication date
JP3406614B2 (ja) 2003-05-12
EP0514357B1 (de) 1996-01-10
HK1005848A1 (en) 1999-01-29
ITRM910327A0 (it) 1991-05-15
EP0514357A1 (de) 1992-11-19
DK0514357T3 (da) 1996-02-26
US5246967A (en) 1993-09-21
JPH05163141A (ja) 1993-06-29
ATE132746T1 (de) 1996-01-15
IT1248321B (it) 1995-01-05
DE69207479T2 (de) 1996-05-23
ITRM910327A1 (it) 1992-11-15

Similar Documents

Publication Publication Date Title
HK127893A (en) Pharmaceutical compositions
DE69207479D1 (de) Verwendung der Ester von Acyl-L-Carnitin mit Gamma-Hydroxy-Buttersäure zur Herstellung von pharmazeutischen Zusammensetzungen zur Behandlung von Lebererkrankungen
TW206970B (de)
AU7772994A (en) Cyclic amino acid derivatives
ATE123944T1 (de) Verwendung von trifluormethylphenyl- tetrahydropyridinen zur herstellung von arzneimitteln zur behandlung anxio-depressiver erkrankungen.
ATE206914T1 (de) Verwendung von ursolsäure zur herstellung eines arzneimittels zur unterdrückung von metastasen
DE68908145D1 (de) Verwendung von l-carnitinderivaten zur herstellung eines arzneimittels zur therapeutischen behandlung von peripheren neuropathien.
DE3873578D1 (de) Verwendung von tetrahydrobenz(c,d)indol-6-carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden.
KR950005823A (ko) 5-아미노-8-메틸-7-피롤리디닐퀴놀린-3-카르본산유도체
ATE206926T1 (de) Verwendung eines phosphorsäurediesters zur herstellung eines arzneimittels zur behandlung von akne
ATE135573T1 (de) Verwendung von indazol-methoxyalkansäure zur herstellung eines arzneimittels zur behandlung von autoimmunkrankheiten
NZ214640A (en) Trienamide derivatives and pharmaceutical compositions having anti-inflammatory and analgesic activity
ATE31022T1 (de) Verwendung von 4,5'-azo-bis-salicylsaeure zur herstellung eines arzneimittels zur behandlung entzuendlicher darmkrankheiten.
ES2058315T3 (es) Compuestos eficaces contra insuficiencia cerebral.
KR910002787A (ko) 아크릴산 아미드유도체, 이들의 제조방법, 이들을 함유하는 약리학적 조성물 및 이들을 사용하는 약품

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee